Shengfang Pharmaceutical Research

Elixir Clinical Research operates as a contract research organization (CRO) based in Shanghai, China, offering a comprehensive suite of services to the life sciences industry. The company was established in 2019 to address the growing needs of pharmaceutical and medical device enterprises.

The firm specializes in managing the entire clinical trial lifecycle, from bioequivalence (BE) studies and Phase I-IV trials to post-marketing and real-world studies. Its service portfolio includes clinical research program design, medical strategy, regulatory registration and affairs, data management, and biostatistics. Elixir Clinical Research aims to enhance the efficiency of clinical research management by integrating digital technologies, such as AI and big data, into its operations. This approach facilitates a data-driven clinical research model intended to provide more transparent project quality control and accelerate the commercialization process for new drugs.

The company serves pharmaceutical companies by providing solutions designed to bring new drugs to market more quickly. In April 2022, Elixir Clinical Research secured $52 million in a Series A funding round. The round was supported by investors including LYFE Capital, Sinovation Ventures, and Chow Tai Fook Enterprises, indicating confidence in the company's tech-driven approach to clinical trials.

Keywords: Contract Research Organization, CRO services, clinical trials, life sciences, pharmaceutical services, drug development, clinical research management, bioequivalence studies, real-world data, data management, biostatistics, regulatory affairs, digital CRO, Shanghai, AI in clinical trials, China life science, pharmaceutical outsourcing, Series A, LYFE Capital, Sinovation Ventures